- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06365476
FlexWave Trial: Effekten av ekstrakorporeal sjokkbølgeterapi ved spastisitet etter slag i øvre lemmer
Effekter av ekstrakorporal sjokkbølge for fleksorspastisitet i øvre lemmer hos slagpasienter: en randomisert kontrollert prøvelse
Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study aimed to evaluate the effects of focused Extracorporeal Shock Wave Therapy (ESWT) on upper limb flexor spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific forearm flexor muscles, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.
The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, hand grip strength, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on upper limb function and spasticity in stroke survivors.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Taipei, Taiwan, 100
- Department of Physical Medicine & Rehabilitation , National Taiwan University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Individuals aged 18 years or older with unilateral cerebral stroke.
- Wrist/finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.
- Stable medical condition and vital signs.
- Conscious and able to comply with instructions.
Exclusion Criteria:
- History of more than one stroke, traumatic brain injury, or cerebral neoplasm.
- Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.
- Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.
- Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.
- Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Focused Extracorporeal Shock Wave Therapy
Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
|
Placebo komparator: Placebo-Controlled Shockwave Therapy
Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
modified Ashworth scale (MAS)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
modified Tardieu scale (MTS) R2-R1 Angle
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Difference between passive range of motion (R2) and the angle of muscle catch (R1), measured in degrees. Larger values indicate greater dynamic spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Tardieu grade
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Spasticity severity (0-5); higher grades indicate greater spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
passive range of motion for the wrist and finger joints
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
the extent to which a joint can be moved without the patient actively participating in the movement |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Medical Research Council (MRC) scale
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
grades voluntary muscle strength on a 0-5 ordinal scale |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
hand grip strength
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
use dynamometer to record the maximum force applied when the patient squeezes it |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Barthel index
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Functional Independence Measure (FIM)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assesses a patient's level of disability and tracks changes over time, with a focus on physical and cognitive functioning across 18 items, scored from 18 (total assistance required) to 126 (fully independent). |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Wolf Motor Function Test (WMFT) Functional ability score
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assess upper extremity function in individuals with neurological impairments, using 15 functional tasks. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Action Research Arm Test (ARAT)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
ultrasound assessment
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
used strain elastography to assess elasticity of forearm muscles |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Shu-mei Yang, MD, National Taiwan University Hospital
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Dymarek R, Taradaj J, Rosinczuk J. Extracorporeal Shock Wave Stimulation as Alternative Treatment Modality for Wrist and Fingers Spasticity in Poststroke Patients: A Prospective, Open-Label, Preliminary Clinical Trial. Evid Based Complement Alternat Med. 2016;2016:4648101. doi: 10.1155/2016/4648101. Epub 2016 Jul 18.
- Cabanas-Valdes R, Calvo-Sanz J, Urrutia G, Serra-Llobet P, Perez-Bellmunt A, German-Romero A. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. Top Stroke Rehabil. 2020 Mar;27(2):137-157. doi: 10.1080/10749357.2019.1654242. Epub 2019 Nov 11.
- Yasar E, Adiguzel E, Kesikburun S, Yenihayat I, Yilmaz B, Alaca R, Tan AK. Assessment of forearm muscle spasticity with sonoelastography in patients with stroke. Br J Radiol. 2016 Dec;89(1068):20160603. doi: 10.1259/bjr.20160603. Epub 2016 Oct 25.
- Jia G, Ma J, Wang S, Wu D, Tan B, Yin Y, Jia L, Cheng L. Long-term Effects of Extracorporeal Shock Wave Therapy on Poststroke Spasticity: A Meta-analysis of Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2020 Mar;29(3):104591. doi: 10.1016/j.jstrokecerebrovasdis.2019.104591. Epub 2019 Dec 31.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Nevrologiske manifestasjoner
- Muskel- og skjelettsykdommer
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Muskelsykdommer
- Muskelhypertoni
- Nevromuskulære manifestasjoner
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Muskelspastisitet
- Slag
- Terapeutikk
- Fysioterapi -modaliteter
- Rehabilitering
- Ultrasonisk terapi
- Diatermi
- Hypertermi, indusert
- Ekstrakorporeal sjokkwaveterapi
Andre studie-ID-numre
- 202309126RIND
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .